Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce, further to its press releases dated February 27, 2025, April 11, 2025 and April 23, 2025, that Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis") has acquired all of the outstanding common shares in the capital of the Company (the "Common Shares"), all outstanding restricted share units (the "RSUs") in the capital of the Company,...
2025-05-27 12:05 PM EDT
Awakn Life Sciences Announces Shareholder Approval of Arrangement
Toronto, Ontario--(Newsfile Corp. - April 23, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce that further to its press releases dated February 27, 2025 and April 11, 2025, the special resolution (the "Special Resolution") in connection with the previously announced statutory plan of arrangement (the "Arrangement") involving the Company and Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis") under the Business Corporations Act (British Columbia) whereby, among other things,...
2025-04-23 7:30 AM EDT
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
Toronto, Ontario--(Newsfile Corp. - April 11, 2025) - Further to its press release dated February 27, 2025 and its management information circular dated May 10, 2025 (the "Circular"), Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company") wishes to provide supplemental disclosure to the Circular in respect of its annual general and special meeting (the "Meeting") of the Company's securityholders (the "Securityholders") to approve, among other things, a statutory plan of arrangement (the "Arrangement")...
2025-04-11 7:30 AM EDT
Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that, further to its press release of December 16, 2024, the Company has entered into an arrangement agreement dated February 22, 2025 (the "Agreement") with Solvonis Therapeutics plc (LSE: SVNS) (formerly, Graft Polymer (UK) PLC) ("Solvonis") setting out the basis...
2025-02-27 9:16 AM EST
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, is pleased to provide an update on its research and development (R&D) programs.Awakn currently has three main R&D programs:1. AWKN-001An investigational, novel combination therapy, consisting of an N-methyl-D-aspartate receptor-modulating drug (ketamine) delivered intravenously (IV) in combination with manualized relapse prevention cognitive behavioral...
2025-01-27 2:00 AM EST
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - January 20, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA), which took place on December 16, 2024. The meeting addressed the continued development of AWKN-002, a proprietary oral thin film (OTF) formulation of esketamine designed...
2025-01-20 5:00 PM EST
Awakn Life Sciences Announces Credit Facility
Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has obtained an unsecured credit facility of up to US$535,000 (the "Facility") from an arm's length creditor of the Company, which can be drawn upon by the Company in multiple advances, and which is evidenced by a grid promissory...
2024-12-18 8:30 AM EST
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has entered into a binding letter of intent (the "LOI") dated December 15, 2024, with Graft Polymer (UK) PLC ("Graft"), pursuant to which Graft would acquire all of the issued and outstanding common shares (the "Common Shares") in the capital...
2024-12-16 8:30 AM EST
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, today announces initial results from a preclinical study of its co-lead aminoindane series (AW21003) conducted by the University of Nottingham. This program focuses on new therapeutic options for trauma-related mental health disorders, particularly Post-Traumatic Stress Disorder (PTSD).Aminoindanes are a class of compounds being explored in...
2024-12-10 5:30 PM EST
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces the opening of four additional clinical trial sites: University Hospitals Sussex NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; Greater Manchester Mental Health NHS Foundation Trust; and University Hospitals Plymouth NHS Trust. This brings the total active trial sites to 7 in...
2024-10-22 7:30 AM EDT
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership with the University of Nottingham, UK. This collaboration focuses on evaluating Awakn's co-lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.The study will be led by Dr. Madeleine King, Assistant Professor in the School of Life...
2024-10-15 7:30 AM EDT
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), today announced the selection of Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of Awakn's New Chemical Entity (NCE) pre-clinical program.Eurofins Discovery, an industry-leading provider of products and...
2024-10-04 7:30 AM EDT
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the size of its previously announced non-brokered...
2024-09-18 7:30 AM EDT
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its pre-clinical program being executed as part of a commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft Polymer"), an innovative healthcare industry services company.The collaboration focuses on developing a new class of therapeutics for the potential treatment of trauma-related...
2024-08-28 7:30 AM EDT
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), announces that the first patient has been screened in the landmark 'MORE-KARE' Phase 3 trial of AWKN-001 for severe AUD. AWKN-001 is an investigational, novel medication-assisted treatment for severe AUD, consisting of an N-methyl-D-aspartate receptor-modulating drug...
2024-08-09 7:30 AM EDT
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Toronto, Ontario--(Newsfile Corp. - July 31, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, and June 4, 2024 it has closed a third tranche of its previously announced non-brokered private placement (the "Offering")...
2024-07-31 7:30 AM EDT
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to provide details of the status of the intellectual property ("IP") portfolio for its aminoindane new chemical entity ("NCE") series program (the "Aminoindane NCEs") being developed in commercial collaboration with Graft Polymer (UK) Plc...
2024-07-22 5:00 PM EDT
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has entered into a commercial collaboration agreement dated July 17, 2024 (the "Collaboration Agreement") with Graft Polymer (UK) Plc (LON: GPL) ("Graft"), an innovative biopolymer drug delivery systems development company....
2024-07-18 7:30 AM EDT
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder, is pleased to announce that, further to its press releases dated April 3, 2024, and April 17, 2024, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering") through the issuance of an...
2024-06-04 7:30 AM EDT
Awakn Life Sciences Discusses Filing of Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited annual financial statements and MD&A for the financial year ended January 31, 2024 (the "Financial Statements") by May 30, 2024, in line with the standard timeline applicable to venture issuers.As previously disclosed...
2024-05-02 6:00 PM EDT